Autism is increasingly discussed in healthcare, education, and social contexts, but sometimes the language used—especially in professional guidance—can be confusing. One phrase that often appears in documents from trusted bodies like the **NICE** (National Institute for Health and Care Excellence) and **GMC** (General Medical Council) is the *"core characteristics of autism."* What does this term mean from a clinical and guidance perspective? How does it help or hinder understanding? And what do the official guidelines say about treatment, especially around the myth that "medicine can treat autism itself"?

Think about it: in this blog post, we'll unpack these important questions with clarity, drawing on the nice guidance library and other key policy resources. I'll also clarify how autism is distinct from co-occurring conditions and highlight the limits of evidence in this space as well as common pitfalls like placebo effects.

Understanding Autism as a Neurodevelopmental Difference, Not an Illness

Before diving into the phrase *core characteristics of autism*, it's essential to understand what autism itself is. Autism is classified as a **neurodevelopmental difference** rather than a disease or illness. That means it's a lifelong variation in brain development that affects social communication, behavior, and sensory experiences.

The **core characteristics of autism** are the fundamental traits or features that help define this neurodevelopmental condition. They do not indicate pathology in the traditional sense but rather a set of developmental differences:



- Challenges in social communication and interaction (e.g., difficulty understanding social cues, forming relationships)
- Restricted and repetitive behaviors, interests, or activities (e.g., strict routines, focused interests, sensory sensitivities)

These two domains form the basis for diagnostic criteria, such as those set out in the DSM-5 and ICD-11, and are reflected in professional guidance like NICE guidance on Autism Spectrum Disorder. They also emphasize that autism is not something to be "cured" or "treated" as an illness, but understood and supported.

What Does "Core Characteristics of Autism" Mean in NICE and GMC Guidance?

Bodies like the **NICE** and **GMC** provide evidence-based guidelines for healthcare professionals working with autistic children and adults. In their guidance documents, the phrase *core characteristics of autism* typically refers to these fundamental diagnostic features.

For example, NICE guideline NG142 on Autism Spectrum Disorder (2017) recommends that assessment and diagnosis focus on these key characteristics while also taking into account co-occurring conditions. The guidance stresses the importance of:

- Identifying support needs related to these core characteristics
- Not medicalizing autism itself but focusing on practical interventions
- Considering the person's individual profile of strengths and difficulties

The **General Medical Council (GMC)**, through its Good Medical Practice and supplementary materials, stresses the ethical responsibility not to misrepresent autism as an illness with a direct pharmacological cure. GMC guidance encourages honest communication with patients about what can be realistically achieved with interventions and treatment.

Important Clarification: Autism vs. Co-occurring Conditions

One critical point emphasized in the NICE guidance library is that evidence-based medicine focuses on treating co-occurring conditions rather than autism itself, because:

- Autism features are developmental, not pathological processes that can be "cured" with drugs.

- Many autistic people have co-occurring conditions like epilepsy, anxiety, ADHD, or sleep disorders that may require treatment.
- Treatment plans should be tailored to these associated conditions, not to autism traits as a whole.

For example, NICE guideline NG99 on Epilepsies in Children and Young People is relevant because epilepsy is seen in up to 20-30% of autistic individuals. However, NICE stresses that epilepsy treatment applies specifically to types like *Dravet syndrome* or *Lennox-Gastaut syndrome*, which are rare and have clear pharmacological pathways, rather than broadly conflating all epilepsy in autistic people.

Narrow Indications in Epilepsy Highlight Evidence Limits

Why mention these specific epilepsy forms? Because it illustrates a crucial point about evidence limits in autism and co-occurring illnesses:

1. **Precision Matters:** Conditions like Dravet syndrome and Lennox-Gastaut syndrome have narrow, well-defined treatment options supported by clinical trials and regulatory approvals.
2. **Generalizations Can Be Harmful:** Extrapolating epilepsy treatment effectiveness to broader autistic populations without these specific diagnoses risks ineffective or unsafe care.
3. **Evidence-Based Medicine Focuses on Symptoms, Not Labels:** NICE and GMC base guidance on strict assessment of symptom benefits rather than anecdotal reports.

"No Medicine for Autism Itself": What NICE Does and Does Not Recommend

The phrase *"No medicine for autism itself"* is often repeated among advocates, clinicians, and guidance documents alike. Here's what NICE says in essence:

- Currently, **no pharmacological treatments** are recommended for the core characteristics of autism. That means no drugs to reduce social communication challenges or repetitive behaviors at the autism level.
- Medicines may have a role for some **associated symptoms or co-occurring conditions**, like anxiety, ADHD, or severe behavioral difficulties, but only after careful assessment.
- The evidence base for medicines targeting co-occurring symptoms is limited, and treatment decisions must be individualized and cautious.

This is a vital stop point for anyone exploring "medicines for autism": if you see claims about "treating autism with cannabis" or similarly sweeping promises, they do not align with current NICE or GMC guidance and often lack rigorous evidence.

Evidence Limits and Placebo Effects in Autism Treatment Claims

The scientific literature on autism and medication is complex and evolving. A few key points about evidence and placebo effects bear emphasizing:

- **Limited High-Quality Trials:** Much research on pharmacological treatments for autism or related behaviors has small sample sizes, high variability, and inconsistent outcomes.
- **The Role of Placebo Effects:** Many reported benefits, such as feeling "calmer" or "less agitated," may not be reliably measured or may reflect placebo responses rather than robust clinical improvements.
- **Importance of Measurable Outcomes:** NICE guidance emphasizes interventions with measurable, validated benefits rather than anecdotal or subjective impressions.

For example, if a parent or practitioner describes a child as being "seems calmer" after trying a new supplement or drug, the guidance would encourage looking for formal measurement tools or clinical assessment to confirm true change and safety.

Summary: What You Need to Remember About "Core Characteristics" Language

Aspect Explanation Core Characteristics of Autism Fundamental neurodevelopmental features defining autism - social communication difficulties and restricted/repetitive behaviors. Autism Is Not An Illness Autism is a lifelong neurodevelopmental difference, not a disease; no "cure" or medicine targets the condition itself. Co-occurring Conditions Many autistic people have associated conditions (e.g., epilepsy, ADHD, anxiety) which may need individual treatment. NICE Recommendations Focus on assessment and support, caution against pharmacological treatment to core traits; evidence supports some medicines for specific co-occurring conditions only. Epilepsy Example Treatment indicated only for narrow epilepsy subtypes like Dravet and Lennox-Gastaut syndromes, not all epilepsy in autism. Evidence and Placebo Effects Evidence base is limited; claims must be backed by measurable outcomes to avoid placebo-driven conclusions.

Final Thoughts

In the NHS context and across healthcare providers in the UK, it's important to approach autism with respect for its nature as a neurodevelopmental difference. The phrase *core characteristics of autism* helps clinicians focus on what defines autism diagnostically, but it does not imply the existence of a medical "treatment" that changes autism itself.

Thanks to the thorough work of organizations like **NICE** and the **GMC**, professionals have clear guidance to avoid unproven, potentially harmful approaches and to concentrate on evidence-based support for autistic individuals and their co-occurring challenges.

For anyone navigating clinical advice https://londoninsider.co.uk/medical-cannabis-and-autism-what-london-families-should-know/ or treatment offers, always double-check:

- Is a treatment targeting autism itself or a co-occurring condition?
- Is there robust evidence supporting this treatment for that condition?
- Are outcomes clearly measurable beyond subjective impressions?
- Does the provider follow up with NICE guidelines and GMC ethical standards?

Understanding the language of core characteristics and guidance can empower better healthcare choices—for autistic individuals, families, and clinicians alike.

For further reading, I recommend visiting the NICE guidance library and checking out GMC's official ethical guidelines.